Tunisia Has 40 Human Medication Production Plants, Covering 80% of Market Needs
Tarek Hammami, President of the National Chamber of the Pharmaceutical Industry (CNIP), announced on Monday, February 9, 2026, that Tunisia has 40 plants for the production of human medications, capable of covering approximately 80% of market needs in terms of quantity and 60% in terms of value.
Key Statistics on Medication Production in Tunisia
- 63% of medications circulating in Tunisia are generics.
- Generics represent 80% of medications available in public hospitals.
- This high proportion highlights the central role of generics in the Tunisian healthcare system, contributing to cost control for patients and the state.
Moving Towards Vaccine Production in Tunisia
Tarek Hammami also discussed the recent visit of Health Minister Mustapha Ferjani to Algeria, aimed at strengthening health and pharmaceutical cooperation between the two countries. According to him, bilateral meetings are planned after the month of Ramadan in Tunisia to consolidate these initiatives and transform exchanges into concrete and strategic projects.
Algerian Pharmaceutical Industry Development
- The Algerian pharmaceutical industry has experienced significant development, with nearly 200 plants, supported by policies protecting local production.
- Measures include banning the importation of generics already produced in Algeria and local production of raw materials.
International Cooperation and Vaccine Production
- For two years, Tunisia has had an agreement with a major international pharmaceutical company to produce vaccines locally, paving the way for expanded cooperation with several countries, including Algeria.
- The Tunisian Ministry of Health confirmed the creation of a joint commission to monitor the results of the Algerian minister's visit and transform them into strategic projects with specific deadlines, emphasizing that political will supports the quality of health services and sanitary security in the region.
